LUS012 / Qilu Pharma - LARVOL DELTA

A HIGHLY SELECTIVE KV1.3 INHIBITOR TARGETING EFFECTOR MEMORY T CELLS DEMONSTRATES SUPERIOR EFFICACY WITH NEAR-COMPLETE HISTOLOGICAL RESOLUTION IN A TNBS-INDUCED IBD MODEL (UEGW 2026) - "From Day –1 to Day 6, rats were orally dosed with LUS012 (1, 3, 10, 30 mg/kg, BID), mesalazine (150 mg/kg, QD), upadacitinib (30 mg/kg, QD), or vehicle (n=6/group). LUS012, a highly selective oral Kv1.3 inhibitor with gut-restricted exposure, achieves potent immunomodulatory effects and near-complete histological resolution in a T-cell-driven colitis model. Its efficacy is superior to standard therapies, and its favorable safety profile supports further clinical evaluation. Targeting TEM cell activation via Kv1.3 inhibition may open new avenues for the treatment of IBD and other TEM-driven autoimmune diseases."

Clinical • Gastroenterology • Gastrointestinal Disorder • Inflammatory Bowel Disease